Drugmakers can boost the effectiveness of clinical research by collaborating with health care providers and regulators to redevelop how treatments are purchased and reviewed, according to a report from PharmaFutures. Regulators should be more flexible, the think tank said. The industry must move from a fixed-price system to one based on how drugs work in clinical practice.

Full Story:

Related Summaries